摘要
目的芎芍胶囊对冠心病介入治疗后再狭窄的影响。方法以2009年1月至2011年1月期间经皮冠状动脉腔内成形术或支架植入术成功的82例冠心病患者为研究对象,随机分为观察组和对照组,每组各41例,对照组给予西医常规治疗,观察组在常规治疗的基础上给予芎芍胶囊口服治疗,随访6个月～2年,观察2组患者在心绞痛发作、血脂变化、冠脉造影再狭窄率、死亡率方面的差别,评价治疗效果。结果观察组2年内复发心绞痛8例,复发率为19.51%,对照组2年内复发心绞痛者19例,复发率为46.34%,P<0.05,差异具有统计学意义;2组患者治疗后血脂均明显降低,但观察组血脂水平下降更为明显,经统计学分析,P<0.05,具有统计学差异;6个月后复查冠脉造影,观察组发生冠脉再狭窄5例,再狭窄率为12.2%,对照组发生冠脉再狭窄13例,再狭窄率为31.71%;2年内2组患者均无患者死亡,死亡率无统计学差异。结论芎芍胶囊具有活血化瘀、通脉止痛的功效,可有效防止介入治疗后冠状动脉发生再狭窄,与西医常规治疗联合应用是一种有效的防止冠心病介入治疗后再狭窄的治疗方法。
Objective XSC on restenosis after percutaneous coronary intervention impact.Methods In January 2009 to January 2011 during percutaneous transluminal coronary angioplasty or successful stent implantation, 82 patients with coronary heart patients in this study were randomly divided into two groups and the control group, n=41 cases, control group received conventional Western treatment, the treatment group given conventional treatment, based on oral treatment XSC, followed up for 6 months to 2 years were observed in patients with angina pectoris, lipid changes, coronary angiography, restenosis rate, death rate differences, evaluation of treatment effect.Results Recurrence of angina pectoris study group 2 years in 8 cases, the recurrence rate was 19.51% in the control group within 2 years, 19 cases of angina recurrence, the recurrence rate was 46.34%, P〈0.05, statistically significant difference; two groups of patients after treatment lipids were significantly reduced, but lipid levels in the observation group decreased more markedly, by statistical analysis,P〈0,05, statistically significant; 6 months after the review of coronary angiography, coronary restenosis observation group occurred in 5 cases, restenosis rate was 12.2% in the control group had 1~ cases of coronary restenosis, restenosis rate was 31.71%; 2 years, two groups of patients with no death,no significant difference in mortality.Conclusion XSC with blood circulation, Tongmai analgesic effect, can effectively prevent the interventional treatment of coronary artery restenosis, in combination with conventional Western medicine is an effective therapy to prevent restenosis after vercutaneous coronary intervention treatment.
出处
《中国卫生产业》
2012年第2期17-18,共2页
China Health Industry
关键词
芎芍胶囊
冠心病介入治疗
再狭窄
预防
影响
XSC
Percutaneous coronary interventionIRestenosis^Prevention
Effects
